<DOC>
	<DOC>NCT02906605</DOC>
	<brief_summary>The purpose of this study is to evaluate if the anti-tumor activity of JNJ-809 combined with apalutamide is improved compared with apalutamide alone for subjects with metastatic castration-resistant prostate cancer (mCRPC).</brief_summary>
	<brief_title>A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms, Castration-Resistant</mesh_term>
	<criteria>Adenocarcinoma of the prostate Metastatic disease as documented by technetium99m (99mTc) bone scan or metastatic lesions by computed tomography (CT) or magnetic resonance imaging (MRI) scans Surgically or medically castrated, with testosterone levels of less than (&lt;)50 nanogram per deciliter (ng/dL) Castrationresistant prostate cancer documented by time to prostatespecific antigen (PSA) increase during continuous treatment with androgen deprivation therapy (ADT) OR radiographic progression of soft tissues OR radiographic progression of bone according to PCWG3 Predominately small cell or neuroendocrine carcinoma of the prostate Known brain metastases (even if treated) or untreated epidural spread Prior chemotherapy for prostate cancer, except if administered in the adjuvant/neoadjuvant setting, or up to 6 cycles of docetaxel for metastatic hormonesensitive prostate cancer Treatment with medications known to lower the seizure threshold or any investigational agent that were not discontinued or substituted greater than or equal to (&gt;=)28 days prior to randomization</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>